BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35587457)

  • 21. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
    Oler E; Eke AC; Hesson A
    Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
    Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB
    Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M; Lyseng-Williamson KA; Deeks ED
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
    Gandell DL; Randell MD; Gudeman JL
    Curr Med Res Opin; 2020 Aug; 36(8):1393-1401. PubMed ID: 32544354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
    Godlewski BJ; Sobolik LI; King VJ; Harrod CS
    Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
    Kuper SG; Abramovici AR; Jauk VC; Harper LM; Biggio JR; Tita AT
    Am J Obstet Gynecol; 2017 Oct; 217(4):476.e1-476.e6. PubMed ID: 28549983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of progestatives for the prevention of spontaneous preterm birth].
    Azria E
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1280-1298. PubMed ID: 27776845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J; Lynne S
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivering equity: preterm birth by socioeconomic class before and after coverage of 17-hydroxyprogesterone caproate.
    Hesson AM; Pitts DS; Langen ES
    J Matern Fetal Neonatal Med; 2022 Dec; 35(24):4713-4716. PubMed ID: 33430664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of progestogens in women with preterm premature rupture of membranes.
    Di Sarno R; Raffone A; Saccone G
    Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF).
    Sentilhes L; Sénat MV; Ancel PY; Azria E; Benoist G; Blanc J; Brabant G; Bretelle F; Brun S; Doret M; Ducroux-Schouwey C; Evrard A; Kayem G; Maisonneuve E; Marcellin L; Marret S; Mottet N; Paysant S; Riethmuller D; Rozenberg P; Schmitz T; Torchin H; Langer B
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():217-224. PubMed ID: 28068594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-examining the Meis Trial for Evidence of False-Positive Results.
    Sibai B; Saade GR; Das AF
    Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck T; Miller HS; Das AF; Birch R; Jozwiakowski MJ
    Am J Perinatol; 2018 Oct; 35(12):1228-1234. PubMed ID: 29702708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.